Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes



Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes (via PR Newswire)

INDIANAPOLIS, Oct. 22, 2012 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type…



 

Leave a Reply

Go Top